Source: PharmaCan Capital Corp. Press Release


TORONTO, ONTARIO–(Marketwired – Feb. 27, 2015) –


PharmaCan Capital Corp. (TSX VENTURE:MJN) (“PharmaCan”) is pleased to announce that The Whistler Medical Marijuana Company (“WMMC”) has received notice from Health Canada confirming the renewal of its Marihuana for Medical Purposes Regulation (“MMPR”) license. PharmaCan has a 21.4% ownership interest in WMMC.

“This is another in a series of incredible milestones for WMMC. Following on the heels of receiving approval from Health Canada to begin producing in three new production rooms in December 2014, this renewal positions WMMC for an incredibly bright future as an integral supplier of medicine under Canada’s MMPR program.” said Paul Rosen, PharmaCan’s President and CEO. Mr. Rosen added that “The unique Whistler brand is already recognized globally, and we are confident that WMMC will become one of the most recognized and respected companies in our emerging industry. 2015 is shaping up to be an incredible year of growth and opportunity for the Whistler Medical Marijuana Company.”

Mr. Rosen continued “Today is a hallmark day for PharmaCan, and its investee companies. With license renewals this week at both Whistler Medical Marijuana and In the Zone, we feel more confident than ever that PharmaCan is building towards creating the most durable income stream generated from the sale of medical marihuana in Canada.”

About PharmaCan Capital Corp.

PharmaCan is a company in the business of investing in companies either licensed, or actively seeking a license, to produce medical marihuana pursuant to Canada’s MMPR. PharmaCan has a diversified portfolio of investments including investments in 5 of the 25 companies licensed by Heath Canada to produce medical marihuana.

About Whistler Medical Marijuana

WMMC, based in Whistler, British Columbia, received its original MMPR license in February 2014. The Fraser Valley Organic Producers Association certifies WMMC as organic. WMMC currently operates out of a 12,500 square foot facility that it owns. It has negotiated an option to purchase the remainder of the units in its building, which when exercised upon, would increase the total facility size to 33,000 square feet. PharmaCan has a 21.4% ownership interest in WMMC.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Investor & Media Relations
PharmaCan Capital Corp.
Paul Rosen
(416) 504-0004
[email protected]

Source: Marketwired (Canada) (February 27, 2015 – 8:56 AM EST)

News by QuoteMedia